Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity?

Mariajoseph-Antony, Lezy Flora; Kannan, A.; Panneerselvam, A.; Loganathan, Chithra; Anbarasu, Kumarasamy; Prahalathan, Chidambaram

doi:10.1016/j.mehy.2020.110201

Cited by 10 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of aquaporins (AQPs) water channels across cell membranes is also important, particularly in lungs, with their isoforms AQP1, AQP3, AQP4 AQP5. 44 All these aspects have a clear clinical value in COVID-19.…”

Section: Discussionmentioning

confidence: 99%

“…We may also consider the role of RL‐PBMT in improving water transport and catabolic evacuation by releasing bound water, facilitating alveolar fluid clearance in pulmonary oedema, hence supporting self‐repair mechanisms and faster return to homeostasis. The role of aquaporins (AQPs) water channels across cell membranes is also important, particularly in lungs, with their isoforms AQP1, AQP3, AQP4 AQP5 44 . All these aspects have a clear clinical value in COVID‐19.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early cases of acute infectious respiratory syndrome treated with photobiomodulation, diagnosis and intervention: Two case reports

Pelletier-Aouizerate

Zivic

2021

Clinical Case Reports

View full text Add to dashboard Cite

A worldwide outbreak of severe acute respiratory syndrome emerged in 2019 and developed in a pandemic of COVID-19. This respiratory βeta-coronavirus is characterized by the severity of its complications, that is acute pulmonary inflammation, pneumonia, lung fibrosis and organ dysfunction, ultimately inducing fatality. Scientists worldwide have focused on finding medication and vaccine for fighting the viral disease, yet its high transmission and mutagenicity renders international efforts challenging. Drugs may also not be the only approach. Previous animal studies on pulmonary infectious diseases and a recent case report of a COVID-19 patient with comorbidities demonstrated the mitigation of inflammatory processes addressed with Infrared Photobiomodulation therapy (IR-PBMT). Here, we report the use of PBMT at different wavelengths and treatment parameters on two patients with acute infectious respiratory syndrome, who may represent early COVID-19 patients in the United Kingdom and France. This case report's dissemination to the broader scientific community is of interest for PBMT was successfully applied according to clinical presentation, double-blind to COVID-19 diagnosis. Two females, mean age 60, manifested signs of acute respiratory infection at the end of 2019. According to the CARE checklist, we retrospectively collected data from patients and screening laboratories to ascertain epidemiological and symptomatologic aspects and reported clinical, laboratory, radiological, scanner and immunology findings. Both patients experienced at the onset of illness fever, burning feeling in the throat, throbbing cough, myalgia, severe fatigue, headache, loss of taste, dyspnoea and pneumonia signs. Symptoms aggravated into chest tightness and respiratory difficulties. One patient experienced diarrhoea and cutaneous manifestations. Patients received PBMT with non-coherent red light (RL) 630 nm and 660 nm, significantly improving oxygenation, respiratory function and inflammatory syndrome, avoiding emergency care. This case report demonstrates the potential clinical value of PBMT in mitigating inflammation, improving respiratory distress and oxygenation at early stages of COVID-19 and in other infectious lung diseases, preventing viral infections complications. It also expands our knowledge on RL and its positive effects

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Early cases of acute infectious respiratory syndrome treated with photobiomodulation, diagnosis and intervention: Two case reports

Pelletier-Aouizerate

Zivic

2021

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

“…Some of the aquaporins, including AQP3, essentially function as water transport pores between the airways and the pulmonary capillaries [40], are key in lung fluid clearance and the formation of this lung oedema as a consequence of the lung injury [36]. In fact, the use of aquaporin modulators in lung inflammation and oedema has been proposed for potential use for the treatment of COVID-19 respiratory comorbidity [41].…”

Section: Discussionmentioning

confidence: 99%

A genome-wide association study of COVID-19 related hospitalization in Spain reveals genetic disparities among sexes

Carracedo

2021

Preprint

View full text Add to dashboard Cite

We describe the results of the Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE). In sex-disaggregated genome-wide studies of COVID-19 hospitalization, we found two known loci associated among males (SLC6A20-LZTFL1 and IFNAR2), and a novel one among females (TLE1). Meta-analyses with independent studies revealed two novel associations (AQP3 and ARHGAP33) and replicated ELF5. A genetic risk score predicted COVID-19 severity, especially among younger males. We found less SNP-heritability and larger heritability differences by age (<60/≥60 years) among males than females. Inbreeding depression was associated with COVID-19 hospitalization and severity, and the effect was stronger among older males.

show abstract

“…All these phenomena collectively may lead to increased pulmonary edema or pulmonary hypertension following SARS-CoV-2 infection. Pulmonary edema rapidly developing in COVID-19 patients with COPD is considered as one of the reasons for death ( Mariajoseph-Antony et al, 2020 ). Transporter proteins such aquaporins, which are in the check point of cellular inflammations and pulmonary edema, may be considered as potential drug targets to modulate their expression levels to mitigate the inflammation-induced comorbidity in COVID-19 patients ( Mariajoseph-Antony et al, 2020 ; Azad et al, 2021 ).…”

Section: Host Response To Sars-cov-2 Varies With Comorbiditiesmentioning

confidence: 99%

“…Pulmonary edema rapidly developing in COVID-19 patients with COPD is considered as one of the reasons for death ( Mariajoseph-Antony et al, 2020 ). Transporter proteins such aquaporins, which are in the check point of cellular inflammations and pulmonary edema, may be considered as potential drug targets to modulate their expression levels to mitigate the inflammation-induced comorbidity in COVID-19 patients ( Mariajoseph-Antony et al, 2020 ; Azad et al, 2021 ). Moreover, a medication strategy of COPD patients had also been claimed to be associated with the risk of COVID-19.…”

Section: Host Response To Sars-cov-2 Varies With Comorbiditiesmentioning

confidence: 99%

Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges

Hakim

Hasan

et al. 2021

Front. Microbiol.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), a pandemic declared by the World Health Organization on March 11, 2020, is caused by the infection of highly transmissible species of a novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As of July 25, 2021, there are 194,372,584 cases and 4,167,937 deaths with high variability in clinical manifestations, disease burden, and post-disease complications among different people around the globe. Overall, COVID-19 is manifested as mild to moderate in almost 90% of the cases and only the rest 10% of the cases need hospitalization. However, patients with older age and those having different comorbidities have made worst the pandemic scenario. The variability of pathological consequences and clinical manifestations of COVID-19 is associated with differential host–SARS-CoV-2 interactions, which are influenced by the factors that originated from the SARS-CoV-2 and the host. These factors usually include the genomic attributes and virulent factors of the SARS-CoV-2, the burden of coinfection with other viruses and bacteria, age and gender of the individuals, different comorbidities, immune suppressions/deficiency, genotypes of major histocompatibility complex, and blood group antigens and antibodies. We herein retrieved and reviewed literatures from PubMed, Scopus, and Google relevant to clinical complications and pathogenesis of COVID-19 among people of different age, sex, and geographical locations; genomic characteristics of SARS-CoV-2 including its variants, host response under different variables, and comorbidities to summarize the dynamics of the host response to SARS-CoV-2 infection; and host response toward approved vaccines and treatment strategies against COVID-19. After reviewing a large number of published articles covering different aspects of host response to SARS-CoV-2, it is clear that one aspect from one region is not working with the scenario same to others, as studies have been done separately with a very small number of cases from a particular area/region of a country. Importantly, to combat such a pandemic as COVID-19, a conclusive understanding of the disease dynamics is required. This review emphasizes on the identification of the factors influencing the dynamics of host responses to SARS-CoV-2 and offers a future perspective to explore the molecular insights of COVID-19.

show abstract

Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity?

Cited by 10 publications

References 38 publications

Early cases of acute infectious respiratory syndrome treated with photobiomodulation, diagnosis and intervention: Two case reports

Early cases of acute infectious respiratory syndrome treated with photobiomodulation, diagnosis and intervention: Two case reports

A genome-wide association study of COVID-19 related hospitalization in Spain reveals genetic disparities among sexes

Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges

Contact Info

Product

Resources

About